ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV..

瑞士祖格和美国波士顿，2024年5月6日（环球通讯社）--Oculis Holding AG（纳斯达克：OCS；西塞州：OCS）（“Oculis”或“公司”）是一家旨在挽救视力和改善眼部护理的全球生物制药公司，今天宣布Oculis的管理层将出席2024年5月14日至16日在内华达州拉斯维加斯举行的美国银行医疗保健会议。。

Riad Sherif, M.D., Chief Executive Officer of Oculis, will deliver a company presentation on Wednesday, May 15th at 11:20am PT at the Encore Hotel. A live webcast of the presentation will be available here.

Oculis首席执行官Riad Sherif医学博士将于5月15日（星期三）上午11:20在安可酒店（Encore Hotel）发表公司演讲。这里将提供演示文稿的在线直播。

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their Bank of America representative to request meetings. A link to access company presentation, when available, will be posted to Oculis website on the Events & Presentation page under the Investors & Media section..

在会议期间，公司将可以进行一对一的会议。感兴趣的投资者应联系他们的美国银行代表要求会面。访问公司演示文稿的链接（如果可用）将发布到Oculis网站的投资者与媒体部分下的活动与演示页面上。。

About Oculis

Empty关于Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02, a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON).

Oculis是一家全球性生物制药公司（Nasdaq:OCS；XICE:OCS），旨在挽救视力和改善眼部护理。Oculis高度分化的产品线包括多个正在开发的创新产品候选产品。它包括OCS-01，一种用于糖尿病性黄斑水肿（DME）和白内障手术后炎症和疼痛治疗的局部滴眼剂候选药物；OCS-02是干眼症（DED）和非感染性前葡萄膜炎的局部生物抗TNFα滴眼剂候选药物；和OCS-05，一种急性视神经炎（AON）的疾病缓解候选者。

Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors..

Oculis总部位于瑞士，在美国和冰岛开展业务，其目标是改善全球患者的健康和生活质量。该公司由经验丰富的管理团队领导，拥有成功的业绩记录，并得到领先的国际医疗保健投资者的支持。。

For more information, please visit: www.oculis.com

有关更多信息，请访问：www.oculis.com

Oculis Contacts

联络

Ms. Sylvia Cheung, CFO

首席财务官Sylvia Cheung女士

sylvia.cheung@oculis.com

sylvia.cheung@oculis.com

Investor & Media Relations

投资者与媒体关系

LifeSci Advisors

LifeSci顾问

Corey Davis, Ph.D.

科里·戴维斯博士。

cdavis@lifesciadvisors.com

cdavis@lifesciadvisors.com

1-212-915-2577

1-212-915-2577